Mar 02, 2017 21:07 pm UTC| Business
Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied Enrollment of the first stage of both NSCLC cohorts completed; decision whether to progress...
Wingstop Inc. Reports Fiscal Fourth Quarter 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
DALLAS, March 02, 2017 -- Wingstop Inc. (NASDAQ:WING) today announced fiscal fourth quarter and fiscal year 2016 financial results for the period ended December31, 2016 and annual guidance for fiscal year 2017. ...
Wingstop Inc. Reports Fiscal Fourth Quarter 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
DALLAS, March 02, 2017 -- Wingstop Inc. (NASDAQ:WING) today announced fiscal fourth quarter and fiscal year 2016 financial results for the period ended December31, 2016 and annual guidance for fiscal year 2017. ...
Wingstop Inc. Reports Fiscal Fourth Quarter 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
DALLAS, March 02, 2017 -- Wingstop Inc. (NASDAQ:WING) today announced fiscal fourth quarter and fiscal year 2016 financial results for the period ended December31, 2016 and annual guidance for fiscal year 2017. ...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
BOSTON, March 02, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
BOSTON, March 02, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
Mar 02, 2017 21:07 pm UTC| Business
BOSTON, March 02, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood